MaxCyte Raises 2026 Revenue Guidance After 26% Q3 Core Growth
MXCT sits 55% above its 52-week low of $0.643.
Summary
MaxCyte pre-announced Q3 core revenue of approximately $8.1 million, up 26% year-over-year, and raised full-year 2026 revenue guidance to approximately $34 million from $30-32 million. The company also lifted core business guidance to approximately $28 million and SPL Program-related revenue to approximately $6 million, citing accelerated instrument purchases from a large customer and a second milestone payment from an SPL partner. This follows a Q2 revenue decline of 15% and a reiterated full-year outlook in August, making the return to double-digit growth a notable inflection. The company will report full Q3 results on November 10, 2026.
At the time of this announcement, MXCT was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.5M. The 52-week trading range was $0.64 to $1.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.